Calpain 3 is important for muscle regeneration: Evidence from patients with limb girdle muscular dystrophies

BMC Musculoskeletal Disorders

Volumn 13, Issue , 2012, Pages

  Hauerslev, Simon ^a   Sveen, Marie Louise ^a   Duno, Morten ^b   Angelini, Corrado ^c,d   Vissing, John ^a   Krag, Thomas O ^a  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF PADOVA   (Italy)

^d IRCCS SAN CAMILLO HOSPITAL   (Italy)

Author keywords

Calpain 3; INF; Limb girdle muscular dystrophy; Muscle regeneration; Neonatal myosin heavy chain; Vimentin

Indexed keywords

BIOLOGICAL MARKER; CALPAIN 3; MYOD PROTEIN; MYOGENIN; MYOSIN HEAVY CHAIN; VIMENTIN; CALPAIN; CAPN3 PROTEIN, HUMAN; DYSTROPHIN; FKRP PROTEIN, HUMAN; LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2A; MUSCLE PROTEIN; MYOD1 MYOGENIC DIFFERENTIATION PROTEIN; MYOG PROTEIN, HUMAN; PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BECKER MUSCULAR DYSTROPHY; CALPAIN 3 DEFICIENCY; CAPN3 GENE; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; GENE; GENE LOCATION; GENE MUTATION; HUMAN; HUMAN TISSUE; LIMB GIRDLE MUSCULAR DYSTROPHY; MALE; MUSCLE CELL; MUSCLE REGENERATION; PHENOTYPE; PROTEIN DEFICIENCY; SARCOMERE; APOPTOSIS; BIOPSY; CHEMISTRY; DENMARK; DUCHENNE MUSCULAR DYSTROPHY; GENETIC PREDISPOSITION; GENETICS; HOSPITALIZATION; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY; REGENERATION; SKELETAL MUSCLE; STATISTICAL MODEL; WESTERN BLOTTING;

ADOLESCENT; ADULT; APOPTOSIS; BIOLOGICAL MARKERS; BIOPSY; BLOTTING, WESTERN; CALPAIN; DENMARK; DYSTROPHIN; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; LINEAR MODELS; MALE; MIDDLE AGED; MUSCLE PROTEINS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHIES, LIMB-GIRDLE; MUSCULAR DYSTROPHY, DUCHENNE; MUTATION; MYOD PROTEIN; MYOGENIN; MYOSIN HEAVY CHAINS; PHENOTYPE; PROTEINS; REGENERATION; SEVERITY OF ILLNESS INDEX; VIMENTIN; YOUNG ADULT;

EID: 84858734537     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-13-43     Document Type: Article

References (47)

1. The clinical course of calpainopathy (LGMD2A) and dysferlinopathy (LGMD2B). Angelini C, Nardetto L, Borsato C, Padoan R, Fanin M, Nascimbeni AC, Tasca E, Neurol Res 2010 32 41 46 10.1179/174313209X380847 20092694
2. Loss of calpain-3 autocatalytic activity in LGMD2A patients with normal protein expression. Fanin M, Nascimbeni AC, Fulizio L, Trevisan CP, Meznaric-Petrusa M, Angelini C, Am J Pathol 2003 163 1929 1936 10.1016/S0002-9440(10)63551-1 14578192 (Pubitemid 37310023)
3. Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Richard I, Broux O, Allamand V, Fougerousse F, Chiannilkulchai N, Bourg N, Brenguier L, Devaud C, Pasturaud P, Roudaut C, et al. Cell 1995 81 27 40 10.1016/0092-8674(95)90368-2 7720071
4. Non-proteolytic functions of calpain-3 in sarcoplasmic reticulum in skeletal muscles. Ojima K, Ono Y, Ottenheijm C, Hata S, Suzuki H, Granzier H, Sorimachi H, J Mol Biol 2011 407 439 449 10.1016/j.jmb.2011.01.057 21295580
5. Dynamic distribution of muscle-specific calpain in mice has a key role in physical-stress adaptation and is impaired in muscular dystrophy. Ojima K, Kawabata Y, Nakao H, Nakao K, Doi N, Kitamura F, Ono Y, Hata S, Suzuki H, Kawahara H, et al. J Clin Invest 2010 120 2672 2683 10.1172/JCI40658 20592470
6. Pathogenity of some limb girdle muscular dystrophy mutations can result from reduced anchorage to myofibrils and altered stability of calpain 3. Ermolova N, Kudryashova E, DiFranco M, Vergara J, Kramerova I, Spencer MJ, Hum Mol Genet 2011 20 3331 3345 10.1093/hmg/ddr239 21624972
7. Multiple molecular interactions implicate the connectin/titin N2A region as a modulating scaffold for p94/calpain 3 activity in skeletal muscle. Hayashi C, Ono Y, Doi N, Kitamura F, Tagami M, Mineki R, Arai T, Taguchi H, Yanagida M, Hirner S, et al. J Biol Chem 2008 283 14801 14814 10.1074/jbc.M708262200 18310072
8. Endogenous calpain-3 activation is primarily governed by small increases in resting cytoplasmic [Ca2+] and is not dependent on stretch. Murphy RM, Lamb GD, J Biol Chem 2009 284 7811 7819 10.1074/jbc.M808655200 19144634
9. Identification of putative in vivo substrates of calpain 3 by comparative proteomics of overexpressing transgenic and nontransgenic mice. Cohen N, Kudryashova E, Kramerova I, Anderson LV, Beckmann JS, Bushby K, Spencer MJ, Proteomics 2006 6 6075 6084 10.1002/pmic.200600199 17051641 (Pubitemid 44851392)
10. Calpain 3 is a modulator of the dysferlin protein complex in skeletal muscle. Huang Y, De Moree A, Van Remoortere A, Bushby K, Frants RR, Dunnen JT, Van Der Maarel S, Hum Mol Genet 2008 17 1855 1866 10.1093/hmg/ddn081 18334579 (Pubitemid 351791513)
11. Calpain 3 is a rapid-action, unidirectional proteolytic switch central to muscle remodeling. de Morree A, Lutje Hulsik D, Impagliazzo A, van Haagen HH, de Galan P, van Remoortere A, 't Hoen PA, van Ommen GB, Frants RR, van der Maarel SM, PLoS One 2010 5 11940 10.1371/journal.pone.0011940 20694146
12. PIAS proteins: pleiotropic interactors associated with SUMO. Rytinki MM, Kaikkonen S, Pehkonen P, Jaaskelainen T, Palvimo JJ, Cell Mol Life Sci 2009 66 3029 3041 10.1007/s00018-009-0061-z 19526197
13. Null mutation of calpain 3 (p94) in mice causes abnormal sarcomere formation in vivo and in vitro. Kramerova I, Kudryashova E, Tidball JG, Spencer MJ, Hum Mol Genet 2004 13 1373 1388 10.1093/hmg/ddh153 15138196 (Pubitemid 38961644)
14. Calpain 3 deficiency is associated with myonuclear apoptosis and profound perturbation of the IkappaB alpha/NF-kappaB pathway in limb-girdle muscular dystrophy type 2A. Baghdiguian S, Martin M, Richard I, Pons F, Astier C, Bourg N, Hay RT, Chemaly R, Halaby G, Loiselet J, et al. Nat Med 1999 5 503 511 10.1038/8385 10229226 (Pubitemid 29220208)
15. Dubowitz V, Sewry CA, Muscle Biopsy-A practical Approach Philadelphia: Saunders 3 2007
16. Level of muscle regeneration in limb-girdle muscular dystrophy type 2I relates to genotype and clinical severity. Krag TO, Hauerslev S, Sveen ML, Schwartz M, Vissing J, Skelet Muscle 2011 1 31 10.1186/2044-5040-1-31 21970816
17. Muscle-specific gene expression in rhabdomyosarcomas and stages of human fetal skeletal muscle development. Tonin PN, Scrable H, Shimada H, Cavenee WK, Cancer Res 1991 51 5100 5106 1717137
18. Myogenic regulatory factors during regeneration of skeletal muscle in young, adult, and old rats. Marsh DR, Criswell DS, Carson JA, Booth FW, J Appl Physiol 1997 83 1270 1275 9338436 (Pubitemid 27433095)
19. A COX-2 inhibitor reduces muscle soreness, but does not influence recovery and adaptation after eccentric exercise. Paulsen G, Egner IM, Drange M, Langberg H, Benestad HB, Fjeld JG, Hallen J, Raastad T, Scand J Med Sci Sports 2010 20 195 e207 10.1111/j.1600-0838.2009.00947.x 19522751
20. Fetal myosin heavy chains in regenerating muscle. Sartore S, Gorza L, Schiaffino S, Nature 1982 298 294 296 10.1038/298294a0 7045696 (Pubitemid 12089422)
21. Identification of skeletal muscle precursor cells in vivo by use of MyoD1 and myogenin probes. Grounds MD, Garrett KL, Lai MC, Wright WE, Beilharz MW, Cell Tissue Res 1992 267 99 104 10.1007/BF00318695 1310442
22. The expression of intermediate filament protein nestin as related to vimentin and desmin in regenerating skeletal muscle. Vaittinen S, Lukka R, Sahlgren C, Hurme T, Rantanen J, Lendahl U, Eriksson JE, Kalimo H, J Neuropathol Exp Neurol 2001 60 588 597 11398835 (Pubitemid 32523623)
23. Diagnostic value of muscle MRI in differentiating LGMD2I from other LGMDs. Fischer D, Walter MC, Kesper K, Petersen JA, Aurino S, Nigro V, Kubisch C, Meindl T, Lochmuller H, Wilhelm K, et al. J Neurol 2005 252 538 547 10.1007/s00415-005-0684-4 15726252 (Pubitemid 40768169)
24. cDNA analyses of CAPN3 enhance mutation detection and reveal a low prevalence of LGMD2A patients in Denmark. Duno M, Sveen ML, Schwartz M, Vissing J, Eur J Hum Genet 2008 16 935 940 10.1038/ejhg.2008.47 18337726
25. Correlations between clinical severity, genotype and muscle pathology in limb girdle muscular dystrophy type 2A. Fanin M, Nardetto L, Nascimbeni AC, Tasca E, Spinazzi M, Padoan R, Angelini C, J Med Genet 2007 44 609 614 10.1136/jmg.2007.050328 17526799 (Pubitemid 47584752)
26. Novel mutations in the calpain 3 gene in Germany. Todorova A, Kress W, Mueller C, Clin Genet 2005 67 356 358 15733273 (Pubitemid 40424833)
27. Analysis of histopathologic and molecular pathologic findings in Czech LGMD2A patients. Hermanova M, Zapletalova E, Sedlackova J, Chrobakova T, Letocha O, Kroupova I, Zamecnik J, Vondracek P, Mazanec R, Marikova T, et al. Muscle Nerve 2006 33 424 432 10.1002/mus.20480 16372320
28. Transcriptional and translational effects of intronic CAPN3 gene mutations. Nascimbeni AC, Fanin M, Tasca E, Angelini C, Hum Mutat 2010 31 1658 E1669 10.1002/humu.21320 20635405
29. Muscle pathology in dysferlin deficiency. Fanin M, Angelini C, Neuropathol Appl Neurobiol 2002 28 461 470 10.1046/j.1365-2990.2002.00417.x 12445162 (Pubitemid 35425599)
30. Reference values of maximum isometric muscle force obtained in 270 children aged 4-16 years by hand-held dynamometry. Beenakker EA, van der Hoeven JH, Fock JM, Maurits NM, Neuromuscul Disord 2001 11 441 446 10.1016/S0960- 8966(01)00193-6 11404114 (Pubitemid 32510003)
31. Reliability of hand-held dynamometry in spinal muscular atrophy. Merlini L, Mazzone ES, Solari A, Morandi L, Muscle Nerve 2002 26 64 70 10.1002/mus.10166 12115950 (Pubitemid 34734397)
32. Morphological and functional study of extensor digitorum longus muscle regeneration after iterative crush lesions in mdx mouse. Louboutin JP, Fichter-Gagnepain V, Pastoret C, Thaon E, Noireaud J, Sebille A, Fardeau M, Neuromuscul Disord 1995 5 489 500 10.1016/0960-8966(95)00006-9 8580731
33. Muscle regeneration in experimental animals and in man. The cycle of tissue change that follows trauma in the injured limb syndrome. Allbrook D, Baker WC, Kirkaldy-Willis WH, J Bone Joint Surg Br 1966 48 153 169 4956072
34. Immobilization of the rabbit tibialis anterior muscle in a lengthened position causes addition of sarcomeres in series and extra-cellular matrix proliferation. Ponten E, Friden J, J Biomech 2008 41 1801 1804 10.1016/j.jbiomech.2008.03.006 18460410
35. NCAM, vimentin and neonatal myosin heavy chain expression in human muscle diseases. Winter A, Bornemann A, Neuropathol Appl Neurobiol 1999 25 417 424 10.1046/j.1365-2990.1999.00178.x 10564532 (Pubitemid 29495690)
36. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. Gavrieli Y, Sherman Y, Ben-Sasson SA, J Cell Biol 1992 119 493 501 10.1083/jcb.119.3.493 1400587
37. New fluorescent microscopical technique in diagnostic microbiology (author's transl). Grossgebauer K, Kegel M, Dann O, Dtsch Med Wochenschr 1976 101 1098 1099 10.1055/s-0028-1104221 819241
38. Molecular and biochemical features of poly (ADP-ribose) metabolism. Lautier D, Lagueux J, Thibodeau J, Menard L, Poirier GG, Mol Cell Biochem 1993 122 171 193 10.1007/BF01076101 8232248 (Pubitemid 23222327)
39. LGMD2I presenting with a characteristic Duchenne or Becker muscular dystrophy phenotype. Schwartz M, Hertz JM, Sveen ML, Vissing J, Neurology 2005 64 1635 1637 10.1212/01.WNL.0000157654.59374.E5 15883334 (Pubitemid 40617709)
40. Does the severity of the LGMD2A phenotype in compound heterozygotes depend on the combination of mutations? Saenz A, Ono Y, Sorimachi H, Goicoechea M, Leturcq F, Blazquez L, Garcia-Bragado F, Marina A, Poza JJ, Azpitarte M, et al. Muscle Nerve 2011 44 710 714 10.1002/mus.22194 22006685
41. A third of LGMD2A biopsies have normal calpain 3 proteolytic activity as determined by an in vitro assay. Milic A, Daniele N, Lochmuller H, Mora M, Comi GP, Moggio M, Noulet F, Walter MC, Morandi L, Poupiot J, et al. Neuromuscul Disord 2007 17 148 156 10.1016/j.nmd.2006.11.001 17236769
42. Satellite cell characterization from aging human muscle. Corbu A, Scaramozza A, Badiali-DeGiorgi L, Tarantino L, Papa V, Rinaldi R, D'Alessandro R, Zavatta M, Laus M, Lattanzi G, et al. Neurol Res 2010 32 63 72 10.1179/174313209X385725 20092696
43. Molecular aging and rejuvenation of human muscle stem cells. Carlson ME, Suetta C, Conboy MJ, Aagaard P, Mackey A, Kjaer M, Conboy I, EMBO Mol Med 2009 1 381 391 10.1002/emmm.200900045 20049743
44. Down-regulation of MyoD by calpain 3 promotes generation of reserve cells in C2C12 myoblasts. Stuelsatz P, Pouzoulet F, Lamarre Y, Dargelos E, Poussard S, Leibovitch S, Cottin P, Veschambre P, J Biol Chem 2010 285 12670 12683 10.1074/jbc.M109.063966 20139084
45. Limb-girdle muscular dystrophy: clinical and pathologic reevaluation. Yamanouchi Y, Arikawa E, Arahata K, Ozawa E, Nonaka I, J Neurol Sci 1995 129 15 20 10.1016/0022-510X(94)00231-C 7751838
46. Functional defects of a muscle-specific calpain, p94, caused by mutations associated with limb-girdle muscular dystrophy type 2A. Ono Y, Shimada H, Sorimachi H, Richard I, Saido TC, Beckmann JS, Ishiura S, Suzuki K, J Biol Chem 1998 273 17073 17078 10.1074/jbc.273.27.17073 9642272 (Pubitemid 28311741)
47. Mutations in calpain 3 associated with limb girdle muscular dystrophy: analysis by molecular modeling and by mutation in m-calpain. Jia Z, Petrounevitch V, Wong A, Moldoveanu T, Davies PL, Elce JS, Beckmann JS, Biophys J 2001 80 2590 2596 10.1016/S0006-3495(01)76229-7 11371436 (Pubitemid 32521635)